156 related articles for article (PubMed ID: 36809238)
1. The metabolism of the dual orexin receptor antagonist daridorexant.
Treiber A; Delahaye S; Weigel A; Aeänismaa P; Gatfield J; Seeland S
Xenobiotica; 2023 Mar; 53(3):173-183. PubMed ID: 36809238
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
Roch C; Bergamini G; Steiner MA; Clozel M
Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
[TBL] [Abstract][Full Text] [Related]
3. Daridorexant in Insomnia Disorder: A Profile of Its Use.
Nie T; Blair HA
CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
[TBL] [Abstract][Full Text] [Related]
4. Daridorexant for the treatment of insomnia disorder: findings and implications.
Dos Santos JBR; da Silva MRR
Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
Ziemichód W; Grabowska K; Kurowska A; Biała G
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
[TBL] [Abstract][Full Text] [Related]
7. Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats.
Steiner MA; Toeroek-Schafroth M; Giusepponi ME; Dacome L; Tessari M
J Psychopharmacol; 2023 Dec; 37(12):1249-1260. PubMed ID: 38059356
[TBL] [Abstract][Full Text] [Related]
8. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
9. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
[TBL] [Abstract][Full Text] [Related]
10. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
11. Daridorexant: First Approval.
Markham A
Drugs; 2022 Apr; 82(5):601-607. PubMed ID: 35298826
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
[TBL] [Abstract][Full Text] [Related]
14. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.
Zammit G; Dauvilliers Y; Pain S; Sebök Kinter D; Mansour Y; Kunz D
Neurology; 2020 May; 94(21):e2222-e2232. PubMed ID: 32341187
[TBL] [Abstract][Full Text] [Related]
15. Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study.
Fernandes M; Placidi F; Mercuri NB; Liguori C
Neurol Sci; 2024 Jul; 45(7):3443-3448. PubMed ID: 38280086
[TBL] [Abstract][Full Text] [Related]
16. Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials.
Jiang F; Li H; Chen Y; Lu H; Ni J; Chen G
Medicine (Baltimore); 2023 Feb; 102(7):e32754. PubMed ID: 36800596
[TBL] [Abstract][Full Text] [Related]
17. Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia.
Najib J; Toderika Y; Dima L
Am J Ther; 2023 Jul-Aug 01; 30(4):e360-e368. PubMed ID: 37449930
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.
Berger B; Kornberger R; Dingemanse J
Eur Neuropsychopharmacol; 2021 Oct; 51():90-104. PubMed ID: 34098518
[TBL] [Abstract][Full Text] [Related]
19. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
[TBL] [Abstract][Full Text] [Related]
20. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.
Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M
Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
